ClinicalTrials.gg
Enrolling by invitationNCT06098898Updated Oct 25, 2023

Safety and Efficacy of NK510 to Treat Gastric Cancer

An Early Phase 1 interventional study of NK510 and Tislelizumab,atezolizumab or Trastuzumab in Gastric Cancer, sponsored by Base Therapeutics (Shanghai) Co., Ltd.. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-10-25.

Sponsored by Base Therapeutics (Shanghai) Co., Ltd. · Early Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Nov 2024, 2 years ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
9
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,184 studies in Stomach Neoplasms with a site in China — 481 open to participants now, 557 under way, 50 of them phase 3. Stomach Neoplasms · China.

Planned enrollment
855th of 881
9 · median 87
Started
2023
with 111 others
Phase 1
93 of 1,184
48 open now
Primary completion
2024-11
later than 84 of 556 live
Registered
760th of 1,184
by date

Among the 1,184 studies in Stomach Neoplasms with a site in China, this one is the 855th largest by planned enrollment of the 881 interventional ones that give a count, is one of 112 that started in 2023, is one of 93 in phase 1, reaches primary completion later than 84 of the 556 other live ones, and was the 760th registered.

Stomach Neoplasms

3,404 studies on the registry are indexed under Stomach Neoplasms; 996 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

481 of the 1,184 studies in Stomach Neoplasms with a site in China are open now. Recruiting first, the newest first:

476 more — sign in →

All 481 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 705 Stomach Neoplasms studies recruiting now, 377 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 70 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,184 studies in Stomach Neoplasms with a site in China, or all of them as a file.
02

Study summary

This study will evaluate the safety and efficacy of NK510 in the treatment of relapsed and refractory advanced gastric cancer.NK510 will be administered in combination with PD-1 blockade or monoclonal anti-HER2 antibody. Patients are required to undergo a biopsy for confirmation of tumor PD-L1 and HER2 expression and. The safety and efficacy of this treatment will be evaluated.

03

Conditions studied

  • Gastric Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age≥18 years;
  • Confirmed by histology or cytology: Adenocarcinoma at the gastric or gastroesophageal junction, with locally advanced unresectable or distant . Tumor tissue can be provided for central laboratory confirmation of and expression status;
  • Received standard treatment before screening, currently in a state of progression or recurrence of the disease;
  • According to v1.1 (Solid Tumor Efficacy Evaluation Criteria), there is at least one CT present;
  • physical status score of 0-2;
  • Expected survival >=3 months;
  • Except for hair loss and fatigue, all previous anti-tumor treatments have alleviated toxicity to level 1 ( v5.0) or original baseline;
  • Female of childbearing age must be non lactating and have a negative serum pregnancy test within 1 week prior to enrollment;
  • Able to follow the research protocol and follow-up process;
  • Voluntarily sign an form to participate in this study.

Exclusion criteria

Exclusion Criteria:

  • Individuals who have previously discontinued treatment with trastuzumab or monoclonal antibody due to intolerance to drug toxicity reactions;
  • Pregnant or lactating female patients;
  • Patients with central nervous system (CNS) and/or cancerous meningitis and obvious symptoms;
  • Having other malignant tumors that require active treatment within the past 3 years;
  • Subjects with active, known or suspected diseases [excluding type I diabetes, hypothyroidism requiring hormone replacement therapy only, skin diseases not requiring systemic treatment (such as vitiligo, psoriasis or alopecia) or diseases that are not expected to recur without external triggers;
  • subjects have a history of immune deficiency, including testing positive, or other acquired or congenital immune deficiency diseases or organ transplantation history;
  • Have a history of serious cardiovascular and cerebrovascular diseases, including but not limited to: severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias requiring clinical intervention, third degree atrioventricular block, etc; At rest, the obtained from a 12 lead examination is>480 ms; Acute coronary syndrome, congestive heart failure, aortic dissection,stroke, or other Grade 3 or above cardiovascular and cerebrovascular events occurred within 6 months prior to enrollment; The (NYHA) has a heart function rating of ≥ II or a (LVEF) of\<50%; Clinically uncontrollable hypertension;
  • Radical radiotherapy was performed within 4 weeks prior to enrollment;Local palliative radiotherapy or Chinese herbal medicine/traditional Chinese patent medicines and simple preparations with anti-tumor indications within 2 weeks before enrollment;
  • Not fully recovered from major surgery or trauma within 2 weeks prior to enrollment;
  • Participated in research drug trials and received research treatment or used research instruments within 4 weeks before enrollment;
  • Other anti-tumor treatments outside of this research protocol are currently underway or planned;
  • Received blood transfusion, erythropoietin, granulocyte colony stimulating factor (G-CSF), or granulocyte macrophage colony stimulating factor treatment within 2 weeks prior to enrollment;
  • Subjects who received systemic treatment with (prednisone>10 mg/day or equivalent) or other /enhancing drugs (such as thymosin, interleukin-2, and interferon) within 2 weeks prior to enrollment. Allowing selected subjects to inhale or topically use corticosteroids in the absence of active autoimmune diseases;
  • The virological examination of or during screening meets any of the following criteria:

    1. HBsAg positive and peripheral blood HBV-DNA titer detection ≥ 1×10\^3 copies/mL or value;
    2. HCV antibody positive;
  • Meet any of the following standards:

    1. Hematological: \<1.5×10\^9/L; count \<75×10\^9/L; \< 9 g/dL;
    2. Hepatic:>3×ULN (tumor liver metastasis ≥ 5×ULN); AST>3×ULN (tumor liver metastasis ≥ 5×ULN); >1.5×ULN or TBIL>2.5(3.0 mg/dL) in Gilbert syndrome subjects;
    3. Renal:Serum creatinine>1.5×ULN or \<50mL/min;
  • Any uncertain factors that affect the safety or compliance of patients;
  • Researchers believe that any other serious or uncontrollable medical disease, active infection,abnormal physical examination, laboratory examination, mental state change, or mental illness increases the risk of the subject or affects the research results.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
9 participants (estimated)

Study arms

  • Experimental
    Group A (low-dose NK510 monotherapy)

    NK510 9×10\^9 NK cells/dose.

    Drug: NK510

  • Experimental
    Group B (low-dose NK510 combined mAbs)

    NK510 9×10\^9 NK cells/dose. PD-1 blockade or anti-HER2 mAbs.

    Drug: NK510 · Drug: Tislelizumab,atezolizumab or Trastuzumab

  • Experimental
    Group C (high-dose NK510 combined mAbs)

    NK510 12×10\^9 NK cells/dose. PD-1 blockade or anti-HER2 mAbs.

    Drug: NK510 · Drug: Tislelizumab,atezolizumab or Trastuzumab

Interventions

  • DrugNK510

    NK510 will be administered through intravenous infusion.3 infusions on Day 0,Day 2 and day 3 for a cycle,for a total of two cycles.

  • DrugTislelizumab,atezolizumab or Trastuzumab

    Administer according to the instructions.

This study also gives Trastuzumab, Atezolizumab. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Dose-Limiting Toxicity

    To evaluate the DLT during N510 treatment

    Time frame: 6 weeks

  2. Maximal Tolerable Dose

    To evaluate the MTD of NK510

    Time frame: 6 weeks

Secondary outcomes

  1. Overall response rate (ORR)

    Effectiveness Metrics

    Time frame: 6 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2023; primary completion for Nov 2024, 12 months later.

Of 167 industry-sponsored phase 1 interventional studies under Stomach Neoplasms, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 65. This study's planned 12 months is below that.

Counting every sponsor, half of 242 studies reached it within 51 months; a quarter within 33 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2023
First posted
Oct 25, 2023
StartEst.
Nov 1, 2023
Primary completionEst.
Nov 1, 2024
CompletionEst.
Nov 1, 2024
Last update
Oct 25, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 25, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06098898
Lead sponsor
Base Therapeutics (Shanghai) Co., Ltd.
Responsible party
Sponsor
First posted
Oct 25, 2023
Start date
Nov 1, 2023 (estimated)
Primary completion
Nov 1, 2024 (estimated)
Completion
Nov 1, 2024 (estimated)
Last update
Oct 25, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Base Edited Natural Killer Cells NK510

Start the discussion